Clinical and Demographic Characteristics of Hospitalized Patients With Xylazine-Related Wounds

Clinical and Demographic Characteristics of Hospitalized Patients With Xylazine-Related Wounds

Published: May/June 2026
Journal Article

Overview

This one-hour, journal article-based activity explores the emerging clinical phenomenon of xylazine-related wounds among patients with substance use disorder. Using data from hospitalized patients in Philadelphia, the article examines patient demographics, substance use patterns, and wound characteristics associated with suspected xylazine exposure. Learners will review how these wounds present clinically, how they may differ from infectious skin and soft tissue conditions, and the challenges clinicians face in diagnosis and management. The activity also explores management considerations, including wound care approaches and antibiotic use, to support accurate recognition and evidence-informed clinical decision-making as xylazine-related presentations expand. 

The target audience for this intermediate continuing education activity includes physicians, nurse practitioners, physician assistants, and other clinicians, researchers, students, and policymakers. 

This activity addresses the following ACGME Core Competencies: Patient Care, Medical Knowledge, and Practice-Based Learning and Improvement.

Abstract

Aims 

Little is known about the demographic and clinical features of patients with xylazine-related wounds. We sought to characterize hospitalized patients with substance use disorder (SUD) and xylazine-related wounds seen for infectious diseases consultation.

Methods

We retrospectively reviewed the medical records of 193 patients diagnosed with SUD at three Philadelphia hospitals between October 2023 and January 2024. Patients were identified as either being diagnosed with (n = 73) or without (n = 120) xylazine-related wounds. We compared the demographic and clinical features between the two groups.

Results

Patients diagnosed with wounds were younger (P <0.001), more likely to be white or Hispanic and less likely to be Black/AA (P <0.001), more likely to have tested positive for fentanyl (P <0.001), amphetamines (P <0.001), and cocaine (P 0.001), more likely to acknowledge injection (P <0.001), and more likely to leave the hospital by patient-directed discharge (PDD) (P <0.001). Most patients had multiple wounds (75%), and more than half (53%) had at least one wound greater than 10 cm at its widest dimension. Although most patients diagnosed with wounds received antibiotics, many did not have symptoms or signs of infection.

Conclusion

Xylazine-related wounds are highly associated with illicitly manufactured fentanyl (IMF) use and with drug injection in the city of Philadelphia. Many patients with xylazine-associated wounds do not have signs of infection and may not benefit from antibiotics. Understanding precisely how xylazine is responsible for wound development and how to best manage the wounds, including wound care and the role of antibiotics, is urgent.

Learning Objectives

Upon completion of this activity, learners will be able to:

1. Identify clinical and demographic characteristics associated with xylazine-related wounds in patients with substance use disorder. 
2. Differentiate xylazine-related wounds from infectious processes based on clinical presentation and associated findings. 
3. Apply evidence-informed strategies to manage xylazine-related wounds, including appropriate use of antibiotics and wound care considerations. 

Registration Rates

*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

Refunds & Cancellations

All ASAM eLearning Center refund requests must be made in writing to education@asam.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been canceled.

Open Registration: 06/02/2026 - 02/10/2029

Close Access Date: 02/10/2029

Course Instructions

1. Click on the Contents tab to begin this activity.
2. Click Download Journal Article in the box titled Journal Article and read the journal article in its entirety. 
3. Click Complete Post-Test to answer multiple-choice questions. You will have 10 attempts to pass and must answer 2 out of 3 questions correctly.
4. Click Complete General Evaluation to provide valuable activity feedback. Scroll down on all questions, as there may be answer options that expand past the size of the window.
5. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

Need Assistance?

For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

ASAM is proud to offer Essential Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

Accreditation & Credits

Joint Accreditation Statement

In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credits Available

• Physicians: 1.00 Credit
• Nurses & NPs: 1.00 Nursing Contact Hour
• PAs: 1.00 Credit
• Pharmacology Hour: 1 Hour
• Interprofessional Continuing Education: 1.00 Credit
• Certified Counselors: NBCC Contact Hours Not Offered

   American Society of Addiction Medicine has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7062. Programs that do not qualify for NBCC credit are clearly identified. American Society of Addiction Medicine is solely responsible for all aspects of the programs.

Maintenance of Certification (MOC)/Continuing Certification Program (CCP)

This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.

• ABIM MOC Points: 1.00 Medical Knowledge
• ABP MOC: 1.00 Lifelong Learning & Self-Assessment
• ABS Continuing Certification: 1.00 Accredited CME
• ABA MOCA 2.0®*: 1.00 Lifelong Learning MOCA 2.0® is a trademark of the American Board of Anesthesiology®. This activity contributes to the CME requirement for Part II: Lifelong Learning and Self-Assessment of the American Board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.

Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.

• American Board of Addiction Medicine (ABAM)
• American Board of Preventive Medicine (ABPM)
• American Board of Psychiatry and Neurology (ABPN)
• Royal College of Physicians and Surgeons of Canada (RCPSC)

Certificates for other professions

All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.

California Association for Drug/Alcohol Educators (CAADE)

This educational program is approved by CAADE: #CP40 999 1225.

California Association of DUI Treatment Centers (CADTP)

This educational program is approved by CADTP: #205.

California Consortium of Addiction Programs and Professionals (CCAPP)

This educational program is approved by CCAPP: #OS-20-330-0227.

Disclosure Information

In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education. 

See the attached article and pdf for a list of disclosures